Sjo È gren's syndrome (SS) is an autoimmune exocrinopathy characterized by mononuclear cell infiltration and loss of parenchymal tissue in salivary and lacrimal glands. The mechanisms for these histologic alterations are not known. Apoptotic cell death, induced by the ligation of Fas (APO-1/ CD95) with Fas ligand (FasL/CD95L) may be an explanation for the tissue damage seen in SS. Fas and FasL were detected in minor salivary glands from SS patients and healthy individuals using immunohistochemical methods. There was increased expression of both Fas and FasL in the patients. The ability of the Fas-FasL pathway to influence epithelial cell growth and survival was demonstrated in vitro using a human submandibular cell line. The presence of Fas receptor was demonstrated on the cells. Anti-Fas antibody triggered cell death. Cells were also grown in the presence of gammainterferon (IFN-g). IFN-g induced an upregulation of Fas receptor expression and pre-treatment of cells with IFN-g led to enhanced anti-Fas mediated cell death.
Introduction
Fas (also termed APO-1 or CD 95) and its ligand (FasL, CD 95L) are cell surface proteins of the TNF receptor/ligand superfamily. After ligation of Fas with FasL, programmed cell death (apoptosis) occurs (Nagata and Golstein, 1995; Itoh et al, 1991) . Monoclonal anti-Fas antibodies have been reported to induce apoptosis in many cell lines (Nakajima et al, 1995 , Matsue et al, 1995 Ni et al, 1994; Ohsako et al, 1994) .
It has been postulated that Fas-mediated apoptosis may play an important role in the development of autoimmunity (Baixeras et al, 1994; Cohen and Duke, 1992) . Fas may also be involved in the pathogenesis of a number of human autoimmune connective tissue disorders, including systemic lupus erythematosus (SLE, Mysler et al, 1994; Emlen et al, 1994) , rheumatoid arthritis (Rose et al, 1994) Hashimoto's thyroiditis (Tanimoto et al, 1995; Giordano et al, 1997) and Sjo È gren's syndrome (SS, Ogawa et al, 1996; Kong et al, 1997) . SS is an autoimmune disorder characterized by oral and ocular dryness, diminished salivary and lacrimal function, and loss of exocrine parenchymal tissues with replacement by an active mononuclear infiltrate (Fox and Kang, 1992) . The mechanisms leading to the tissue changes seen in SS are not fully understood. Recently, Fas receptor has been identified on salivary epithelial cells in human labial minor salivary glands of SS patients (Jonsson et al, 1994; Kong et al, 1997) ; leading to speculation that this cell surface receptor may be involved in the immunopathogenesis of this disorder.
Fas receptor may play a role in the pathogenesis of SS in a number of ways. As an example, reduced apoptosis, brought about by defects of the Fas receptor, could result in the accumulation of autoreactive T-cells in the exocrine glands, as is proposed in the MRL/lpr mouse (WatanabeFukunaga et al, 1992; Singer et al, 1994) . Alternatively, Fas-mediated apoptosis within the salivary gland environment could be a mechanism leading to the loss of epithelial secretory cells via a mechanism of`cellular suicide' (Williams, 1997) . In the present study, we have used in situ immunohistochemical staining to detect Fas and FasL on sections from salivary glands of SS patients. Since animal models for SS are imperfect (Mountz and Gause, 1993) , a well-characterized human submandibular gland cell line, termed HSG, was studied for the ability to undergo Fas-mediated apoptosis and for upregulation of the Fas receptor by cytokines, which have been identified at the site of tissue involvement in autoimmune disorders.
anti-FasL. The pattern of staining was similar to that seen with the anti-Fas Ab. Figure 1C demonstrates the slight background staining when reacting the section with non-specific rabbit IgG Ab. Pre-incubation of the polyclonal Ab with Fas peptide prior to application on the section resulted in complete elimination of reactivity. Figure 1D and E are sections of minor gland tissue from a healthy control reacted with the anti-Fas and anti-FasL Ab, respectively. A similar pattern of staining was found as with the SS samples. All minor glands tested had similar staining patterns for Fas and FasL, including the healthy control tissues. Figure 1 Histochemical staining of minor salivary gland sections from a SS patient (A ± C) and a healthy control (D ± E). (A) represents staining after treating the section with a rabbit polyclonal anti-Fas Ab. The *symbols mark acinar cells, the single arrows (/) infiltrating lymphocytes, and the double arrows (⇓) point to ducts. In (B) the section was reacted with a polyclonal anti-FasL Ab. (C) is a section from the same specimen stained with a control polyclonal rabbit IgG Ab to demonstrate non-specific background reactivity. (D) is a section from a healthy control gland reacted with anti-Fas Ab and (E) was reacted with anti-FasL Ab. The overall staining intensity (mean of three examiners) for these sections was (A) lymphocytes = 4, ducts = 2, acini = 4.3; (B) lymphocytes = 4.3, ducts = 2, acini = 5; (D) lymphocytes = 0.5, ducts = 0, acini = 0.6; and (E) lymphocytes = 0.6, ducts = 1, acini = 1
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A comparison between the Fas and FasL staining in SS patients and healthy volunteers
The bar graphs shown in Figure 2 Figure 3A demonstrates Fas receptor expression (shaded peak) of HSG cells grown in media alone. Figure 3B demonstrates the increase in Fas receptor expression following 3 days treatment of the HSG cells with 1000 units/mL IFN-g.
Effects of anti-Fas on the growth of HSG cells
Addition of anti-Fas Ab to HSG cells resulted in a dosedependent reduction in cell growth at 3 days ( Figure 4A ). Doses of 0.01, 0.5, and 1.0 mg/mL had significant inhibitory effects compared to control media. At 3 days, cell growth was reduced by approximately 35% at the higher doses and for subsequent experiments a dose of 0.5 mg/mL was used. When cells were incubated for 6 days with this concentration of anti-Fas, the cell number was reduced by almost 70% ( Figure 4B ). Cells were examined by FACScan for the presence of DNA fragmentation after 3 days of treatment with 0.5 mg/mL anti-Fas ( Figure 5 ). Compared to the cells cultured with a control mouse IgM antisera (9.3% Figure 5A ) or media alone (11.3% Figure 5B ), there was a significant increase in the percentage of cells exhibiting subdiploid DNA, consistent with apoptotic cell death, in the anti-Fas-treated cells (25.1% Figure 5C ).
The presence of internuclosomal DNA fragmentation was confirmed by TBE polyacrylamide gel electrophoresis of DNA extracted from control and anti-Fas treated cells ( Figure 6 ). Cells grown for 6 days with 0.5 mg/mL anti-Fas (lanes 2 and 4) demonstrated a ladder pattern, characteristic of apoptosis, while control cells (lanes 3 and 5) did not. Similar results could be demonstrated at 3 days, as well (data not shown).
Effects of IFN-g and anti-Fas, combined treatment, on the growth of HSG cells HSG cells were grown with IFN-g for 3 days. The media was changed and the final 3 days of culture were in the presence Figure 2 Mean staining intensity for all sections of SS (N=ten patients) and healthy (N=seven subjects) labial minor salivary glands (A) represents staining intensity for Fas reacted with the polyclonal rabbit Ab, and (B) shows the staining intensity for FasL Figure 3 Expression of Fas receptor by HSG cells. In (A) cells were grown for 3 days in media and then reacted with mouse IgM (2.5 mg/ml, dashed line) or anti-human Fas antibody (2.5 mg/ml, shaded peak). In (B) cells were grown for 3 days in IFN-g (1000 U/ml) and then exposed to anti-Fas antibody (2.5 mg/ ml, solid line). Cells were then reacted with FITC-labeled anti-mouse immunoglobulin antibody and examined by FACScan. The shaded peak in (B) represents the fluorescence for cells grown in media alone and reacted with anti-Fas antibody (as in A). The results shown are representative of experiments done at least three times of either control media (no further IFN-g was added) or 0.5 mg/ mL anti-Fas. Control cells were grown in media alone for 3 days and then fresh media or anti-Fas was added for the next 3 days. As shown previously (Wu et al, 1994) , the IFN-g treated cells initially were growth arrested, but began to grow after removal of the cytokine. However, with addition of antiFas, there was a rapid and significant further reduction in cell number in the IFN-g pre-treated cells. Cell number was reduced within 24 h and the cells remained in profound growth arrest for the remainder of the culture period (Figure 7) . Addition of anti-Fas to the control cells resulted in a slowing of cell growth but not the rapid cell death seen in the IFN-gtreated cells. Significant differences were found at day 6 between each of the treatment groups and the control. There were also significant differences between the groups treated with anti-Fas and IFN-g+ anti-Fas (p50.0001) and between the IFN-g and IFN-g+anti-Fas-treated groups (P50.0001).
In order to demonstrate that reduced cell numbers found following anti-Fas treatment of IFN-g-treated cells were, in fact, induced by Fas/FasL interactions, a competitive inhibitor of Fas/Fas ligand interactions, rhAPO-1/Fas : FcIgG (FasFc), was used. Cells were grown in media ( Figure  8A ) or IFN-g ( Figure 8B ) for 4 days. Fresh media was added and cells were grown for an additional 36 h in the presence of media alone, media + 0.5 mg/mL anti-Fas, or media + 0.5 mg/mL anti-Fas + 5 mg/mL FasFc. As shown above, in control cells ( Figure 8A ), addition of 0.5 mg/mL anti-Fas induced a modest but significant (p50.005) reduction in cell number. When FasFc was added with the anti-Fas antibody, there was no reduction in cell number and no significant differences compared to the control. When cells were grown first in the presence of IFN-g ( Figure 8B ), there was a more pronounced effect of the anti-Fas antibody on survival (480% reduction in cell number, p50.001), as shown earlier. When 5 mg/mL FasFc was added with the anti-Fas, there was still a significant decrease in cell number (%50% reduction, p50.005), however, cell survival was significantly greater in the anti-Fas+FasFc-treated group compared to anti-Fas alone (P50.001).
Discussion
Fas receptor has been reported previously to be present in healthy oral gingival tissues (Yoshioka et al, 1996) and is felt to be part of a normal cell turnover mechanism. Fas and FasL have also been recognized in SS (Jonsson et al, 1994; Kong et al, 1997) . In the present study, labial minor salivary glands from healthy individuals and SS patients were found to express Fas and FasL. However, salivary gland tissues from SS patients had increased intensity of staining compared to the control tissue. This upregulation of Fas and FasL suggests that increased Fas-mediated apoptosis could be a means by which salivary epithelial cells in SS are lost. Although the loss of secretory epithelial cells in SS is well described, the precise mechanism leading to this loss is not known. The increase in Fas and its ligand on the epithelial cells in the SS patients could lead to killing of the functional parenchyma, loss of secretory function, and the subsequent symptoms of oral dryness and salivary gland dysfunction. Figure 5 Cell death and DNA integrity in anti-human Fas-treated HSG cells. The cells were grown for 3 days in media + IgM (A), media alone (B), or media + antihuman Fas antibody (0.5 mg/ml, C). The presence of nuclear fragmentation was determined by FACScan analysis following propidium iodide staining, as described. The percentage of cells with subdiploid DNA (indicated by the bar labeled`M') increased in the anti-Fas-treated cells to 25.1%, compared to the media (11.3%) and the IgM-treated groups (9.3%). These data are representative of experiments done at least three times To examine the possible effects of Fas-FasL interactions of salivary tissues, we used HSG cells which demonstrate many functional responses common to salivary epithelial cells (e.g. He et al, 1989; Royce et al, 1993) and have been shown to both produce and be responsive to cytokines (Shirasuna et al, 1981; Katz et al, 1994) . Results of studies with the HSG cell line may by illuminating of the mechanisms of exocrine tissue damage in SS. We found that HSG cells express Fas and that anti-Fas Ab can induce HSG cell death.
The percentage of cell death induced by anti-Fas varies greatly depending on the cell population (Nakajima et al, 1995; Matsue et al, 1995; Ni et al, 1994; Baixeras et al, 1994; Ju et al, 1995) . Typically, lymphoid cell death exceeds 90% within 24 h, although this is partly dependent on the antibody ligand used (Ju et al, 1995) . Epithelial cells demonstrate markedly slower death kinetics and the killing is substantially less (Matsue et al, 1995) . Results were similar in our study. However, by extending the period of exposure of the HSG cells to anti-Fas Ab to 6 days, we achieved a reduction in cell number of approximately 70% (Figure 3) .
Exposure of cells, including epithelial cell lines, to IFN-g has been shown to increase anti-Fas-mediated apoptosis (Nakajima et al, 1995; Ni et al, 1994; Baixeras et al, 1994; Firestein et al, 1995) . We found similar effects of IFN-g treatment of HSG cells in the present study. We also noted a significant increase in the effects of anti-Fas antibody on HSG cells either pre-treated (Figure 7 ) or incubated concomitantly with IFN-g (data not shown). This is relevant to the clinical state in SS, since IFN-g has been shown to be present in the salivary environment in SS and thus may be involved in the upregulation of Fas on epithelial cells in vivo.
The present studies demonstrate that HSG death observed with anti-Fas treatment is due, at least in part, to apoptotic mechanisms. The increase in 52 n DNA seen ( Figure 5 ) following anti-Fas treatment is consistent with apoptotic cell death and the appearance of a DNA`ladder' (Figure 6 ), considered the biochemical hallmark of apoptosis, following anti-Fas treatment provides evidence for apoptotic cell death in this cell line.
Further evidence that the cell death observed is induced by anti-Fas is provided by the experiments utilizing FasFc. This recombinant molecule, composed of the extracellular domain of human Fas fused to the Fc portion of human IgG1, has been shown to inhibit Fasmediated apoptosis competitively (Alderson et al, 1995) . We found (Figure 8 ) that addition of this compound with anti-Fas blocked cell death of the control cells and significantly increased cell survival in the IFN-g-treated cells, which exhibit increased Fas expression. In the latter experiments, inhibition of cell death was significant but was not complete. We speculate that higher concentrations of FasFc might lead to greater inhibition of anti-Fasinduced cell death. It is also possible that the observed cell death in the IFN-g-treated cells is due, in part, to other than Fas-mediated interactions.
Recent reports have stressed the role of Fas in other autoimmune conditions, including Type I diabetes (Chervonsky et al, 1997 ) and Hashimoto's thyroiditis (Giordano et al, 1997) . FasL has also been suggested to play an esential role in development of hepatitis (Kondo et al, 1997) . The increased expression of both Fas and FasL in the salivary glands of SS patients argues for a substantial role for these molecules in this disorder, as well. Specifically, this is a possible mechanism by which the epithelial secretory cells may be lost in SS. It is Figure 7 Anti-human Fas antibody-mediated effects on IFN-g-treated HSG cells. Cells were treated for 3 days with IFN-g, 1000 U/ml, or were grown in media alone. For the final 3 days, cells were grown with either media or anti-human Fas antibody, 0.5 mg/ml. IFN-g was not present during this final culture period. Data are the mean (+S.E.M.) of three experiments each done in triplicate. At day 6, there were significant differences between each of the treatment groups and the control. There were also significant differences between the media + anti-Fas and the IFN-g + anti-Fas groups (P50.0001) and between the IFN-g + media and IFN-g + anti-Fas groups (P50.0001) Figure 8 Inhibition of anti-human Fas antibody-mediated effects on IFN-gtreated HSG cells with rhAPO-1/Fas : Fc-IgG (FasFc). Cells were treated for 4 days with IFN-g (B), 1000 U/ml, or were grown in media alone (A). For the next 36 h, in both A and B, cells were grown with either media alone (column 1); anti-human Fas antibody (AF), 0.5 mg/ml (column 2); or AF+FasFc, 5 mg/ml (column 3). IFN-g was not present during this final culture period. Data are the mean (+S.E.M.) of three experiments each done in quadruplicate. *denotes a significant reduction in cell number compared to cells grown in media alone. In the IFN-g-treated HSG cells (B), # denotes a significant reduction in cell number of the AF group compared to the AF + FasFc-treated cells significant that the intensity of Fas expression on the acini and ducts of the SS glands did not correlate with the focus scores, a measure of the intensity of mononuclear cell infiltration in these tissues. This implies that Fas expression is not simply responding to the infiltrating cells, but is a response to the underlying systemic autoimmunity. This is supported by the finding of a strong postive correlation (P=0.009) between a systemic serologic indicator of disease activity in SS (serum IgG) and Fas expression on the epithelial cells.
Fas and FasL were seen on the healthy control glands, as well. In the healthy, non-autoimmune gland, Fas and FasL likely are active in normal cell turnover. In SS, we hypothesize that IFN-g (and potentially other cytokines) in the salivary microenvironment induces upregulation of epithelial Fas and FasL, thereby increasing apoptotic cell death and leading to loss of exocrine function. Testing of this hypothesis in cell culture and animal model systems may suggest new therapeutic approaches for this inadequately treated condition.
Materials and Methods
Immunohistochemical staining
Minor salivary glands were obtained from SS patients for diagnostic purposes and from healthy volunteers (ten SS patients and seven healthy glands). Sections were formalin fixed and paraffin embedded. Sections were deparaffinized using xylene (three times 20 min). The slides were stained using an AEC kit (HistoStain SP kit, Zymed, San Francisco, CA, USA) with the following first antibodies: (i) a murine monoclonal anti-Fas antibody (ZB-4 clone, Upstate Biotechnology Inc, Lake Placid, NY, USA); (ii) a rabbit polyclonal anti-Fas Ab (SC-715 clone, Santa Cruz Biotechnology, Santa Cruz, CA, USA); and (iii) a rabbit polyclonal anti-FasL Ab (SC-957, Santa Cruz Biotechnology). Controls included isotype matched Ab (Mouse IgG1, Sigma Immuno Chemicals, St. Louis, MO, USA and normal rabbit IgG, Santa Cruz Biotechnology). Binding specificity was demonstrated also by blocking experiments where polyclonal Ab (SC-715) was incubated for 1 h with Fas peptide (Santa Cruz Biotechnology) prior to application on the tissue sections.
The staining of ducts, acini, and mononuclear infiltrating cells (if present) was evaluated by three independent observers in a blinded method on a scale of 0 ± 5 (0=no staining; 5=maximum staining). The results were summarized and expressed as the mean staining intensity for each specimen. Staining intensity was correlated with a number of clinical disease parameters in the SS patients.
Cell line and culture conditions HSG cells, a generous gift of Dr. Mitsunobu Sato of Tokushima University, Japan, were cultured in Eagle's minimal essential medium (EMEM) (Biofluids, Rockville, MD, USA) supplemented with 10% fetal calf serum (Biofluids), 2 mM L-glutamine, 1000 units/ml penicillin and 100 mg/ml streptomycin at 378C with 5% CO 2 . For each experiment, confluent cells were dissociated with trypsin (NIH Media Unit, Bethesda, MD, USA) washed once with phosphate-buffered saline, (PBS, pH 7.4, Quality Biological, Inc., Gaithersburg, MD, USA) and 25 000 cells per well were placed into 12-well tissue culture plates (Becton-Dickinson, Lincoln Park, NJ, USA). After 24 h, fresh media and the various additions, as noted, were added to the cultures.
Thereafter, media and additions were changed every 3 days for all experiments. Cell number was assessed using a hemocytometer with the 0.4% trypan blue exclusion technique. All experiments were performed in triplicate.
Treatment of cells with anti-Fas and FasFc
Cells were cultured in the presence of 0.5 mg/ml of anti-human Fas (mouse monoclonal IgM, clone CH-11, Upstate Biotechnology Inc., Lake Placid, NY, USA) which recognizes human cell surface Fas. The above concentration was established after several growth inhibition experiments. Cell numbers were measured daily up to 6 days employing the method described above. A mouse IgM antiserum was used as an isotype control. In certain experiments, the anti-human Fas antibody was added in the presence of 5 mg/mL recombinant human APO-1/ Fas : Fc-IgG (FasFc, Alexis Corp., San Diego, CA, USA), which will competitively inhibit the activity of human and mouse APO-1/Fas ligand.
Treatment of cells with IFN-g
HSG cells were plated as described above. After 24 h, the media was changed and 1000 units/ml IFN-g (recombinant human IFN-g. Biosource International, Camarillo, CA, USA) were added based on previously reported dose response studies (Wu et al, 1994) .
FACS analysis for the presence of Fas receptor 5 6 10 6 cells/10 ml were plated on 100 6 20 mm tissue culture dishes (Becton Dickinson, San Jose, CA, USA) and grown for 3 days with 1000 U/ml IFN-g or media alone. Cells were harvested with trypsin, centrifuged at 1000 r.p.m. for 5 min and re-suspended in PBS containing 1% bovine serum albumin (BSA, Sigma). The cells were treated with anti-human Fas (2.5 mg/ml) followed by staining with fluorescein (FITC)-labeled anti-mouse immunoglobulins antibody. Data were collected on a FACScan flow cytometer using CELL FIT software (Becton Dickinson).
FACS analysis for the presence of 52 n DNA Untreated cells and cells treated with anti-human Fas or mouse IgM were plated on tissue culture dishes (5 6 10 6 cells/10 ml) for 3 days. Cells were harvested with trypsin, centrifuged at 1000 r.p.m. for 5 min and suspended in PBS containing 1% BSA. Cells were stained with propidium iodide (cycle test plus DNA kit, Becton-Dickinson) and examined with the FACScan flow cytometer.
DNA extraction and acrylamide gel electrophoresis
Untreated cells and cells treated with anti-human Fas (0.5 mg/ml) were plated on tissue culture dishes (5 6 10 6 cells/10 ml) for 6 days. Floating and adherent cells were collected by trypsinization. Cells were washed three times in 10 ml PBS at room temperature and the cell pellets stored at 7708C. Genomic DNA (gDNA) was extracted using a DNA Extraction Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's recommendations. Electrophoresis of RNAse-treated gDNA (10 mg/lane) was carried out on 4 ± 20% TBE.
Statistical methods
Data were analyzed first by one way repeated measures analysis of variance. Significant differences were resolved by Dunnett's pairwise multiple comparison procedure or individual t-tests. An a level of 0.05 was considered significant. Correlations between SS disease variables and intensity of Fas and FasL staining were done with Pearson and Spearman correlations.
